home *** CD-ROM | disk | FTP | other *** search
/ 2,000 Greater & Lesser Mysteries / 2,000 Greater and Lesser Mysteries.iso / drugs / drugman / tab3-1 < prev    next >
Encoding:
Text File  |  1994-06-10  |  2.8 KB  |  64 lines
  1.  
  2.    Table 3-1. Pharmacokinetic properties and doses of Group IA 
  3.       antiarrhythmic drugs.
  4.       Presc  Cat  contains  the  controlled  drug  <tab1-1>
  5.       and  FDA  pregnancy safety prescribing category codes <tab1-2>
  6.       Calculate dose for significantly over/underweight patient: <newcalc>
  7.    _________________________________________________________________________
  8.    Drug                 Recommended  Half- Plasma level          
  9.    (Available           Dose      life  Thera- Toxic          Presc
  10.        as)              (mg)            peutic         Route   Cat    Notes
  11.    ________________________________________(mg/L)___________________________
  12.    GROUP IA:
  13.    Disopyramide (Toxicity: <tox3 -disopyramide>)
  14.    (generic,Norpace:100,150 mg caps)    
  15.                  100-200 QID  4-10    2-8   >9     Oral   Rx;C    1
  16.        controlled release: 100, 150 mg caps
  17.                   200-400 BID                 Oral
  18.  
  19.    Procainamide (Toxicity: <tox3 -Procainamide>)
  20.    (generic, Pronestyl: 250,375,500 mg tabs, caps,
  21.    100,500 mg/mL injection)
  22.                500-1000 Q3-4hr 2.5-4.5  4-8  >16    Oral    Rx;C
  23.  
  24.                                                        (PgDn key for scroll)
  25.    _________________________________________________________________________
  26.    Drug                 Recommended  Half- Plasma level          
  27.    (Available           Dose      life  Thera- Toxic          Presc
  28.        as)              (mg)            peutic         Route   Cat    Notes
  29.    ________________________________________(mg/L)___________________________
  30.    Procainamide, sustained release
  31.    (generic, Procan-SR: 250,500,750,1000 mg tabs)
  32.               750-1500  QID                     2
  33.                 
  34.    Quinidine      (Toxicity: <tox3 -quinidine>)              
  35.     sulfate                       6-8     3-6  >8            Rx;C
  36.    (generic, 83% quinidine base: 100,200,300 mg tabs,caps;
  37.    200 mg/mL injection)
  38.                      200    once                    Oral or IM Test dose
  39.                200-300 Q6-8hr             Oral  Maintenance
  40.                300-600                IV   Inject diluted
  41.                                         solution slowly
  42.     sulfate  
  43.     (Quinidex: 300 mg SR tabs)                           3
  44.                300-600 Q8-12hr
  45.  
  46.  
  47.  
  48.                                                        (PgDn key for scroll)
  49.  
  50.     gluconate (62% quinidine base)
  51.    (generic, Duraquin: 324,330 mg SR tabs; 80 mg/mL injection)          
  52.               330-660 Q8-12hr            Oral sustained release
  53.               300-600                IV   Inject diluted
  54.                                     solution slowly
  55.     polygalacturonate  (60% quinidine base)
  56.        (Cardioquin: 275 mg tabs)    
  57.               275-550 Q8-12hr            Oral
  58.    =========================================================================
  59.    Footnotes:
  60.    1. CR caps: controlled release capsules.
  61.    2. Sustained release procainamide is preferred by many clinicians  because
  62.       the half-life of regular procainamide is very short.
  63.    3. SR: sustained release forms.
  64.